213 related articles for article (PubMed ID: 38682272)
1. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
Cho H; Kim K
Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
3. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
[TBL] [Abstract][Full Text] [Related]
4. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy.
Shim MK; Song SK; Jeon SI; Hwang KY; Kim K
Expert Opin Drug Deliv; 2022 Jun; 19(6):641-652. PubMed ID: 35603410
[TBL] [Abstract][Full Text] [Related]
5. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
6. Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better.
Thiruppathi J; Vijayan V; Park IK; Lee SE; Rhee JH
Front Immunol; 2024; 15():1375767. PubMed ID: 38646546
[TBL] [Abstract][Full Text] [Related]
7. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
Zhou L; Zhang P; Wang H; Wang D; Li Y
Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102
[TBL] [Abstract][Full Text] [Related]
8. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
Qi J; Jin F; Xu X; Du Y
Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
10. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
11. Electromagnetic Nanomedicines for Combinational Cancer Immunotherapy.
Li J; Luo Y; Pu K
Angew Chem Int Ed Engl; 2021 Jun; 60(23):12682-12705. PubMed ID: 32671893
[TBL] [Abstract][Full Text] [Related]
12. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
13. Nano-Delivery of Immunogenic Cell Death Inducers and Immune Checkpoint Blockade Agents: Single-Nanostructure Strategies for Enhancing Immunotherapy.
Moon Y; Cho H; Kim K
Pharmaceutics; 2024 Jun; 16(6):. PubMed ID: 38931916
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.
Duan X; Chan C; Lin W
Angew Chem Int Ed Engl; 2019 Jan; 58(3):670-680. PubMed ID: 30016571
[TBL] [Abstract][Full Text] [Related]
15. An ultrasound-activated nanoplatform remodels tumor microenvironment through diverse cell death induction for improved immunotherapy.
Ma J; Yuan H; Zhang J; Sun X; Yi L; Li W; Li Z; Fu C; Zheng L; Xu X; Wang X; Wang F; Yin D; Yuan J; Xu C; Li Z; Peng X; Wang J
J Control Release; 2024 Jun; 370():501-515. PubMed ID: 38703950
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines as enhancers of tumor immunogenicity to augment cancer immunotherapy.
Dogheim GM; El Feel NE; Abd El-Maksod EA; Amer SS; El-Gizawy SA; Abd Elhamid AS; Elzoghby AO
Drug Discov Today; 2024 Mar; 29(3):103905. PubMed ID: 38295898
[TBL] [Abstract][Full Text] [Related]
17. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Li E; Huang X; Zhang G; Liang T
J Exp Clin Cancer Res; 2021 Sep; 40(1):279. PubMed ID: 34479614
[TBL] [Abstract][Full Text] [Related]
18. Activating Nanomedicines with Electromagnetic Energy for Deep-Tissue Induction of Immunogenic Cell Death in Cancer Immunotherapy.
Wang F; Pu K; Li J
Small Methods; 2023 May; 7(5):e2201083. PubMed ID: 36316270
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of immunogenic cell death in cancer immunotherapy.
Arimoto KI; Miyauchi S; Liu M; Zhang DE
Front Immunol; 2024; 15():1390263. PubMed ID: 38799433
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.
Ji B; Wei M; Yang B
Theranostics; 2022; 12(1):434-458. PubMed ID: 34987658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
